Tel Aviv, Israel: The use of medical cannabis mitigates many of the side-effects associated with cancer chemotherapy, such as pain and nausea, according to data published in the international medical journal Acta Haematologica.
Israeli researchers assessed the efficacy of medical cannabis administration in controlling chemotherapy-induced adverse effects in patients with Hodgkin lymphoma (HL). They reported that the use of cannabis was associated with improvements in subjects’ pain relief, nausea, appetite, and general well-being.
“Medical cannabis use is prevalent in this HL cohort, and appears to be effective in ameliorating chemotherapy-related AEs (adverse events),” authors concluded.
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Medical cannabis use by Hodgkin lymphoma patients: Experience of a single center,” appears in Acta Haematologica.